| Cat.No. | Name | Information |
|---|---|---|
| M9416 | Durvalumab | Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1. |
| M9236 | Ranibizumab | Ranibizumab (RG-6321) is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A. Ranibizumab binds and inhibits vascular endothelial growth factor-a (VEGF-a) to inhibit neoangiogenesis. |
| M8984 | Denosumab | Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. |
| M8941 | Fenebrutinib | GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK. |
| M6222 | Adalimumab | Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD. |
| M6104 | Ipilimumab | Ipilimumab (MDX-010, BMS-734016) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. |
| M6103 | Cetuximab | Cetuximab is a chimeric IgG1 monoclonal antibody to EGFR that inhibits the interaction of EGFR with its ligand. For use in cellular assays, human IgG antibody can be used as an isotype control. (For human and non-humanized mice). |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M3849 | Aflibercept | Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization. |
| M3847 | Alemtuzumab | Alemtuzumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that is directed against the 21-28 kDa cell surface glycoprotein CD52. Alemtuzumab does not cross-react with mouse CD52, making in vivo studies in wild-type mice unfeasible. |
| M3814 | Sarilumab | Sarilumab is a human recombinant IgG1 antibody that binds to both forms of interleukin 6 receptors (IL-6R), thus inhibiting the IL-6-mediated signaling. |
| M1629 | Ramucirumab | Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). |
| M1622 | Secukinumab | Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is the first-in-class anti-IL-17 agent to be used in studies of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. |
| M1621 | Ustekinumab | Ustekinumab is a human monoclonal antibody that targets IL12 and IL23, natural proteins that regulate the immune system and immune-mediated inflammatory diseases. |
| M1618 | Vedolizumab | Vedolizumab is a humanized monoclonal antibody that specifically antagonizes Integrin (α4β7) and inhibits the binding of α4β7 to the intestinal mucosal cell adhesion molecule MADCAM-1. Vedolizumab is indicated for humanized mice. |
| M1616 | Daratumumab | Daratumumab (Daratumumab) is a first-in-class, specific anti-CD38 monoclonal antibody (IgG1). (for human or immunodeficient mice). |
| M1615 | Obinutuzumab | Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20. |
| M1598 | Eculizumab | Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species. |
| M1595 | Evolocumab | Evolocumab (AMG 145) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. |
| M1545 | Infliximab | Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that blocks TNF-α interaction with TNF-α receptor 1 (TNFR1) and TNFR2. For the treatment of autoimmune diseases. Infliximab is available in BALB/ C or C57/Bl6 mice. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
